Award

National Cancer Institute 1R01CA291848-01A1

Targeting EZH2 in advanced prostate cancer

Recipient

National Cancer Institute (NCI), part of the NIH

Award Amount

$497,972.00

Ceiling

$497,972.00

Awarded

March 30, 2026

Identifier

1R01CA291848-01A1

Award for research to develop and evaluate EZH2-targeting therapies for advanced prostate cancer using PROTAC technology.

Description

This NIH grant aims to develop and evaluate EZH2-targeting therapies for advanced prostate cancer, including CRPC, using PROTAC technology and preclinical models.

View original record